# Novartis

Organization · id `cardio:novartis` · Cardiovascular Atlas · release `5dcd9b263fe17744` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Novartis AG; Novartis Pharmaceuticals

## In plain language

Novartis is a Swiss drug company. It makes Leqvio (inclisiran), is a collaborator on the ORION-4 inclisiran outcome trial, and sponsored the Lp(a)HORIZON trial of pelacarsen, which it reported in September 2026 had missed its main goal.

## Technical summary

ROR record 02f9zrr09, Switzerland, listed with the types company and funder. The Leqvio label record gives Novartis Pharmaceuticals Corporation as manufacturer and the US drug-approvals database gives NOVARTIS as applicant on NDA214012. ClinicalTrials.gov lists Novartis Pharmaceuticals as lead sponsor of Lp(a)HORIZON (NCT04023552) and as a collaborator on ORION-4 (NCT03705234). The registry names the entity Novartis Pharmaceuticals and the ROR record names the parent company; this page treats them as one organization for navigation.

## Connected pages

- Manufactures: Sacubitril/valsartan (Entresto) (`cardio:entresto`)
- Manufactures: Inclisiran (Leqvio) (`cardio:leqvio`)
- Sponsors: ORION-4 (inclisiran outcome trial) (`cardio:orion-4`)
- Sponsors: PARADIGM-HF (`cardio:paradigm-hf`)

## Provenance

Content hash: 5fb1984c457a00e924ddc97de0b108647524d5f11f3e068e03b8ac054385a21c
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-14